Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL5734118 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL122053 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29376790 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL466397 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19469505 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29757195 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5556077 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19023 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5735765 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL2118157 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120924-B1 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-20120251643-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110045108-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | ZADEC APS (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | SCHERING CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2120924-A2 | AN ANTI-DIABETIC EXTRACT OF HONEYBUSH | Zadec APS (DK) | 2009-11-25 | — | — | EP | disclosed |
| US-7612058-B2 | Methods for inhibiting sterol absorption | SCHERING CORPORATION (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1799263-A4 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2002096415-A2 | USE OF AZETIDINONE SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | SCHERING CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058685-A2 | COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058733-A2 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002058696-A2 | THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEROLEMIA | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151536-A1 | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | PPARG, PPARA, PPARD | PPARG 1/4885RARG 117/4885RXRA 37/4885 |
| US-20110045108-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | IAPP, DPP4, DPP3 | PPARG 1228/4885RARG 3879/4885RXRA 4253/4885 |
| US-20120251643-A1 | ANTI-DIABETIC EXTRACT OF HONEYBUSH | IAPP, DPP4, DPP3 | PPARG 1228/4885RARG 3879/4885RXRA 4253/4885 |
| US-20100291034-A1 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | CYP3A43, CYP3A4, CYP3A7 | PPARG 1660/4885RARG 2228/4885RXRA 1846/4885 |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | FBP1, SLC5A1, ALDOA | PPARG 2273/4885RARG 4803/4885RXRA 4555/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | PPARG 769/4885RARG 917/4885RXRA 643/4885 |
| US-20020169134-A1 | Use of substituted azetidinone compounds for the treatment of sitosterolemia | CYP46A1, CYP27A1, CYP51A1 | PPARG 1488/4885RARG 2581/4885RXRA 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.